November 23, 2021
3 min watch
Save
VIDEO: Orasis completing phase 3 presbyopia drop trial
BOSTON – Orasis Pharmaceuticals anticipates finishing its phase 3 program involving CSF-1 ophthalmic solution for treating presbyopia this year, President and COO Paul Smith said here at the American Academy of Optometry meeting.
“NEAR-1 and NEAR-2, together with our phase 2b study, will form a program in which CSF-1 has been studied in more than 700 patients,” he said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Smith reports being president and COO of Orasis.
Read more about